Evidence map›Paper›PMID 40325622›Full record

ArticleCNS neuroscience & therapeutics2025

S-9-PAHSA Protects Against High-Fat Diet-Induced Diabetes-Associated Cognitive Impairment via Gut Microbiota Regulation.

Shanshan Huang, Xinru Wang, Meng Wang, Jinhong Lin, Jiaoqi Ren, Chenyu Lu, Jiayu Fu, Yanli Zhang, Xuechun Wang, Jichang Xiao and 2 more

Abstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. CTNNB1 Genetic Variation and Its Interaction With DLK1 in Type 2 Diabetes Mellitus.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shanshan HuangDepartment of Geriatric of Huashan Hospital, National Clinical Research Center for Aging and Medicine, Fudan University, Shanghai, China.ORCID 0000-0002-4018-820X
Xinru WangDepartment of Geriatric of Huashan Hospital, National Clinical Research Center for Aging and Medicine, Fudan University, Shanghai, China.
Meng WangDepartment of Geriatric of Huashan Hospital, National Clinical Research Center for Aging and Medicine, Fudan University, Shanghai, China.
Jinhong LinState Key Laboratory of Fluorine and Nitrogen Chemistry and Advanced Materials, Chinese Academy of Sciences, Shanghai, China.
Jiaoqi RenDepartment of Geriatric of Huashan Hospital, National Clinical Research Center for Aging and Medicine, Fudan University, Shanghai, China.
Chenyu LuDepartment of Translational Neuroscience, Jing'an District Centre Hospital of Shanghai, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, and Institutes of Brain Science, Fudan University, Shanghai, China.
Jiayu FuDepartment of Geriatric of Huashan Hospital, National Clinical Research Center for Aging and Medicine, Fudan University, Shanghai, China.
Yanli ZhangDepartment of Geriatric of Huashan Hospital, National Clinical Research Center for Aging and Medicine, Fudan University, Shanghai, China.
Xuechun WangDepartment of Geriatric of Huashan Hospital, National Clinical Research Center for Aging and Medicine, Fudan University, Shanghai, China.
Jichang XiaoState Key Laboratory of Fluorine and Nitrogen Chemistry and Advanced Materials, Chinese Academy of Sciences, Shanghai, China.ORCID 0000-0001-8881-1796
Jingchun GuoDepartment of Translational Neuroscience, Jing'an District Centre Hospital of Shanghai, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, and Institutes of Brain Science, Fudan University, Shanghai, China.
Houguang ZhouDepartment of Geriatric of Huashan Hospital, National Clinical Research Center for Aging and Medicine, Fudan University, Shanghai, China.ORCID 0000-0002-5550-1166

Funding

National Key R&D Program of China 2021YFE0111800National Science Foundation 81671392National Science Foundation 81871098Shanghai Municipal Key Clinical Specialty shslczdzk02802
6 · The paper itself

Abstract

aimDiabetes-associated cognitive impairment (DACI) is a common complication of Type 2 diabetes mellitus (T2DM), with its mechanisms and treatments for DACI remaining incompletely clarified. This study investigated the protective efficacy of the novel lipid S-enantiomer of 9-palmitic acid esters of hydroxy stearic acids (S-9-PAHSA, S9P) in a high-fat diet-induced DACI mouse model.

methodsMice were randomly assigned to three groups: normal diet (ND), high-fat diet (HFD), and HFD + 30 mg/kg/day S9P (HFD + S9P). Fasting blood glucose (FBG), intraperitoneal glucose tolerance test (IPGTT), and insulin tolerance test (ITT) were conducted to assess blood glucose homeostasis. Morris Water Maze and Y maze tests evaluated cognitive function, and neuronal status was examined through pathological analysis, Golgi staining, and transmission electron microscopy (TEM). Colonic barrier integrity was assessed using periodic acid-Schiff and Alcian blue staining (AB-PAS) and immunohistochemistry (IHC) staining. Intestinal microbiota composition was analyzed by 16S rDNA sequencing, and serum metabolic characteristics were determined by metabolomics sequencing.

resultsS9P improved glucose homeostasis and alleviated cognitive decline in DACI mice. It also mitigated neuronal damage, dendritic degeneration, and synaptic damage, while restoring colonic barrier integrity and ameliorating gut microbiome imbalances, insulin resistance, and lipid imbalance. Additionally, S9P regulated metabolite profiles and the PI3K/AKT/mTOR signaling pathways, and reduced astrocyte activation and neuroinflammatory responses in the hippocampus of HFD-induced DACI mice.

conclusionS9P had a protective effect against HFD-induced diabetic cognitive impairment closely related to the modulation of the gut-brain axis, suggesting that S9P has the potential to become a new therapeutic approach for DACI.

Indexed as

Cognitive DysfunctionDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Diet, High-FatGastrointestinal MicrobiomeStearic AcidsAnimalsBlood GlucoseMaleMiceMice, Inbred C57BLBlood GlucoseStearic Acidsdiabetes‐associated cognitive impairmentgut microbiotaPI3K/AKT/mTORS‐9‐PAHSAsynaptic dysfunction

Identifiers

PMID40325622
PMCPMC12052735

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.